/
Other
Pain
42
Pipeline Programs↗
172
Active Trials↗
57
Companies Involved↗
Pain is a moderately active landscape with 42 programs across 57 companies. The most active players are Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Tanabe Pharma America, Inc., GSK. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical34
Phase 35
Approved
No programs
Analysis
Modality Breakdown
95%
Small molecule
36 of 38 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 93% of 42 pipeline programs.
Analysis
Trial Status
433
clinical trials
Completed201 · 46%
Recruiting88 · 20%
Not yet recruiting48 · 11%
Active, not recruiting26 · 6%
Unknown status25 · 6%
Terminated18 · 4%
Other27 · 6%
Clinical Trials
Trial Activity
433 trials
Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder
Recruiting·—·Phase 4·NCT06803485·84 enrolled
Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience
Recruiting·—·Phase 1·NCT05074485·70 enrolled
Dronabinol as an Adjunct for Reducing Pain
Recruiting·—·Phase 2·NCT06454669·75 enrolled
Ginger Root Extract for Sciatic Pain Individuals
Recruiting·—·Phase 2·NCT06817018·80 enrolled
Neural and Psychological Mechanisms of Pain Perception
Recruiting·NNational Center for Complementary and Integrative Health (NCCIH)·Preclinical·NCT02446262·550 enrolled
Page 1 of 29
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)